Harbor Investment Advisory LLC Sells 2,042 Shares of AbbVie Inc. $ABBV

Harbor Investment Advisory LLC decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 9.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,050 shares of the company’s stock after selling 2,042 shares during the period. Harbor Investment Advisory LLC’s holdings in AbbVie were worth $4,361,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ABBV. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter valued at $26,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the 4th quarter worth $28,000. Westend Capital Management LLC bought a new stake in shares of AbbVie in the 4th quarter worth $29,000. Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter valued at about $31,000. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ABBV. Morgan Stanley boosted their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Canaccord Genuity Group increased their price objective on shares of AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Wells Fargo & Company set a $260.00 target price on shares of AbbVie in a research report on Monday, June 22nd. Guggenheim restated a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.81.

AbbVie Trading Down 1.1%

AbbVie stock opened at $251.45 on Wednesday. AbbVie Inc. has a 12 month low of $184.38 and a 12 month high of $255.99. The business’s 50 day simple moving average is $216.92 and its 200 day simple moving average is $219.56. The company has a market cap of $444.26 billion, a price-to-earnings ratio of 123.87, a PEG ratio of 0.78 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the firm posted $2.46 EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, equities research analysts forecast that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported positive Phase 3 results for Epkinly/epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, with the trial meeting its primary endpoint and suggesting a potential label expansion. Article Title
• Positive Sentiment: AbbVie received positive CHMP opinions in Europe for Rinvoq in severe alopecia areata and non-segmental vitiligo, which could broaden the drug’s addressable market and add future sales momentum if approved. Article Title
• Positive Sentiment: AbbVie’s newly announced $10.9 billion Apogee acquisition and other partnership milestones underscore management’s willingness to invest heavily in future growth and deepen its immunology and neurology pipeline. Article Title
• Neutral Sentiment: Analysts slightly trimmed FY2026 earnings estimates, but the revised forecast remains close to consensus, so this looks like a modest rather than a major headwind. Article Title
• Negative Sentiment: U.S. lawmakers opened an investigation into AbbVie’s clinical trials in China, citing possible national security, ethical, and data-protection concerns. Article Title

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.